p53 activation of mesenchymal stromal cells partially abrogates microenvironment-mediated resistance to FLT3 inhibition in AML through HIF-1 -mediated down-regulation of CXCL12

FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo

(2011) T. Sato et al.   BLOOD

SOCS3 regulates graft-versus-host disease

(2010) G. R. Hill et al.   BLOOD

FLT3 as a therapeutic target in AML: still challenging after all these years

(2010) T. Kindler et al.   BLOOD

Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia

(2010) J. Long et al.   BLOOD

Autocrine Induction of Invasive and Metastatic Phenotypes by the MIF-CXCR4 Axis in Drug-Resistant Human Colon Cancer Cells

(2010) Anne-Frédérique Dessein et al.   CANCER RESEARCH

Phase I study of sorafenib in patients with refractory or relapsed acute leukemias

(2010) G. Borthakur et al.   HAEMATOLOGICA

CXC Chemokine Receptor 4 Is a Cell Surface Receptor for Extracellular Ubiquitin

(2010) Vikas Saini et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia

(2010) Farhad Ravandi et al.   JOURNAL OF CLINICAL ONCOLOGY

Drug resistance in mutant FLT3-positive AML

(2010) E Weisberg et al.   ONCOGENE

FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation

(2009) G. Yoshimoto et al.   BLOOD

Survivin mediates aberrant hematopoietic progenitor cell proliferation and acute leukemia in mice induced by internal tandem duplication of Flt3

(2009) S. Fukuda et al.   BLOOD

AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)

(2009) P. P. Zarrinkar et al.   BLOOD

KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation

(2009) Y. Shiotsu et al.   BLOOD

Nutlin-3, an Hdm2 antagonist, inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated inactivation of HIF-1α

(2009) Yoon-Mi Lee et al.   CARCINOGENESIS

Doxorubicin: The Good, the Bad and the Ugly Effect

(2009) Cristina Carvalho et al.   CURRENT MEDICINAL CHEMISTRY

A functional heteromeric MIF receptor formed by CD74 and CXCR4

(2009) Verena Schwartz et al.   FEBS LETTERS

Dissection of PIM serine/threonine kinases in FLT3-ITD–induced leukemogenesis reveals PIM1 as regulator of CXCL12–CXCR4-mediated homing and migration

(2009) Rebekka Grundler et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Selective FLT3 inhibitor FI-700 neutralizes Mcl-1 and enhances p53-mediated apoptosis in AML cells with activating mutations of FLT3 through Mcl-1/Noxa axis

(2009) K Kojima et al.   LEUKEMIA

AMD3100 Is a CXCR7 Ligand with Allosteric Agonist Properties

(2009) I. Kalatskaya et al.   MOLECULAR PHARMACOLOGY

New agents in acute myeloid leukemia: Beyond cytarabine and anthracyclines

(2009) Amir T. Fathi et al.   Current Oncology Reports

CXCR4 expression and biologic activity in acute myeloid leukemia are dependent on oxygen partial pressure

(2008) M. Fiegl et al.   BLOOD

A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response

(2008) K. W. Pratz et al.   BLOOD

Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML

(2008) Z. Zeng et al.   BLOOD

Unique Biology of Mcl-1: Therapeutic Opportunities in Cancer

(2008) Gordon Shore et al.   CURRENT MOLECULAR MEDICINE

Mutant FLT3: A Direct Target of Sorafenib in Acute Myelogenous Leukemia

(2008) Weiguo Zhang et al.   JNCI-Journal of the National Cancer Institute

Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition

(2008) S. Shangary et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA